Cell Banking Outsourcing Market Report 2026

The cell banking outsourcing market size has grown rapidly in recent years. It will grow from $12.86 billion in 2025 to $14.76 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to growth in biologics manufacturing, increasing reliance on outsourced bioprocessing services, expansion of vaccine production programs, rising need for standardized cell line storage, cost optimization by pharmaceutical companies.

The cell banking outsourcing market size is expected to see rapid growth in the next few years. It will grow to $24.12 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to surge in cell and gene therapy pipelines, rising demand for viral vector manufacturing, increasing regulatory focus on cell line traceability, growth of personalized medicine development, expansion of contract development and manufacturing organizations. Major trends in the forecast period include rising outsourcing of gmp-compliant cell banking services, increasing demand for multi-species cell banking capabilities, standardization of cell line documentation and traceability, expansion of viral and vector cell banking for advanced therapies, growing preference for long-term cell bank storage agreements.

The growing prevalence of chronic diseases is anticipated to boost the cell banking outsourcing market in the years ahead. Chronic diseases represent long-term health conditions that emerge slowly and endure for prolonged durations, typically demanding continuous care. This escalating burden stems from shifts in lifestyles, aging demographics, and hereditary factors. The cell banking outsourcing market aids research into chronic diseases by offering dedicated facilities, cutting-edge tools, and specialized expertise for the effective storage, maintenance, and handling of cells essential to therapy development. For instance, in April 2025, the NHS Confederation - a UK-based national body - reported that by 2035, around 17% of the UK population might be managing four or more chronic conditions. Thus, the increasing load of chronic diseases is fueling expansion in the cell banking outsourcing market.

Major companies in the cell banking outsourcing market are prioritizing the creation of cutting-edge technologies, like single-cell potency characterization platforms, to provide more accurate potency evaluations and aid in producing superior cell therapies. A single-cell potency characterization platform is a sophisticated analytical tool built to assess the functional attributes and therapeutic promise of individual cells in diverse cell populations, offering detailed understanding of cell dynamics, potency, and modes of action for research and clinical applications. For example, in January 2024, Cellply Srl, an Italian biotechnology firm, introduced VivaCyte, a comprehensive single-cell potency characterization platform that combines potency analysis with immunophenotyping, offering full automation, single-cell precision, and fast multi-parameter functional evaluation to cut down on development timelines, expenses, and risks while allowing thorough assessment of various cell therapy candidates across different process variations.

In April 2025, Artis BioSolutions LLC, a US-based healthcare technology company, acquired Landmark Bio for an undisclosed sum. Through this acquisition, Artis seeks to expand Landmark’s expertise in translational research and GMP manufacturing, speeding up the development and commercialization of advanced cell and gene therapies. Landmark Bio, PBLLC, is a US-based life sciences firm offering cell banking outsourcing services.

Major companies operating in the cell banking outsourcing market are Lonza Group Ltd., WuXi AppTec, Charles River Laboratories, Labcorp Drug Development, Covance Inc., SGS Life Sciences, Sartorius AG, BioReliance, Cleancells, Clean Biologics, Texcell, Goodwin Biotechnology Inc., Perfectus Biomed Limited, BioStorage Technologies Inc., Toxikon Corp., PX’Therapeutics SA, Sigma-Aldrich Co. Ltd., Transcell Biolife Pvt Ltd, Eurofins Scientific SE, ViruSure GmbH.

North America was the largest region in the cell banking outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell banking outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell banking outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created both operational challenges and strategic shifts for the cell banking outsourcing market by increasing the cost of imported cryogenic equipment, bioprocessing consumables, and quality testing reagents essential for cell bank preparation and characterization. these cost pressures have most significantly impacted viral cell banking and master cell banking segments, particularly across north america and europe where regulatory-grade inputs are heavily imported. asia-pacific outsourcing hubs have also experienced delays due to cross-border logistics disruptions. however, tariffs have encouraged regional localization of cell banking infrastructure and strengthened domestic outsourcing capabilities, supporting long-term supply chain resilience.

The cell banking outsourcing market research report is one of a series of new reports that provides cell banking outsourcing market statistics, including cell banking outsourcing industry global market size, regional shares, competitors with a cell banking outsourcing market share, detailed cell banking outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cell banking outsourcing industry. This cell banking outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell banking outsourcing involves hiring outside companies to create, sustain, and oversee repositories of vital cell lines used in biotechnology and pharmaceutical sectors, including drug development and biomanufacturing. This approach guarantees that cells are processed, preserved, and cared for according to uniform standards, promoting reliability and uniformity.

The primary categories of cell banking outsourcing encompass master cell banking, working cell banking, and viral cell banking. Master cell banking (MCB) involves a stock of thoroughly characterized cells derived from a single clone, designed to act as the initial source for manufacturing therapeutic products like biologics or cell therapies. It covers diverse cell types, including stem cell banking and non-stem cell banking, across multiple stages such as bank storage, bank characterization and testing, and bank preparation.

The cell banking outsourcing market includes revenues earned by entities by providing services, such as cell line establishment, cryopreservation, cell line characterization, facilitating the distribution of cell lines, and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.